Three clinical isolates of Staphylococcus aureus resistant to gentamicin and other aminoglycosides have been examined for antibiotic modifying enzymes. The strains contain a number of these enzymes, most of them similar to those commonly found in aminoglycoside-resistant gram-negative strains. All three strains (and a transductant derived from one of them) contain two enzymes mediating gentamicin resistance, an aminoglvcoside 6'-N-acetyltransferase and a novel enzyme, gentamicin phosphotransferase.
There have been a number of recent reports of gentamicin resistance in clinical isolates of Staphylococcus aureus. Soussy et al. (6) reported plasmid-coded resistance to gentamicin, kanamycin, and tobramycin and suggested that a single modifying enzyme was responsible. An inactivating enzyme was also implicated in a gentamicin-resistant strain isolated by Porthouse et al. (5) . Speller et al. (7) demonstrated the presence of an acetyltransferase and an adenylyltransferase, both inactivating gentamicin, kanamycin, and tobramycin, and a second adenylyltransferase, inactivating streptomycin.
A number of gentamicin-resistant strains of S. aureus have recently been isolated in two Cambridge hospitals. The epidemiology of these strains and the transduction of resistance by means of a phage isolated from one of them have been described by Warren (manuscript submitted for publication).
The mechanisms of resistance to gentamicin in these strains are examined here to test further the suggestion that most antibiotic resistance mechanisms will be basically similar in all bacteria (3) . There are at present five known aminoglycoside-modifying enzymes that mediate resistance to gentamicin in gram-negative bacteria, namely, aminoglycoside 6'-N-acetyltransferase, aminoglycoside 2"-adenylyltransferase, and three distinct aminoglycoside acetyltransferases (4) .
In this report the aminoglycoside-modifying enzymes in the Cambridge strains are characterized, and a previously undescribed enzyme (a gentamicin-kanamycin-tobramycin phosphotransferase) is demonstrated. Preparation of cell-free extracts. Cells were grown by diluting 0.5 ml of an overnight culture into 100 ml of medium (grams per liter: tryptone, 10; yeast extract, 5; and NaCl, 10). Flasks were incubated at 370C with shaking until the late logarithmic phase of growth. Cells were harvested, washed once in buffer I {0.01 M tris(hydroxymethyl)-aminomethane[Tris]-hydrochloride, pH 7.8, 0.01 M MgC12, 0.025 M NH4CI, 0.001 M dithiothreitol}, and frozen at -20°C. Frozen cell pellets (approximately 0;5 g, wet weight) were ground with alumina, 3 to 4 ml of buffer I was added, and the lysate was spun at a low speed to remove alumina and unbroken cells. The crude extract was spun at 105,000 x g for 90 min, and 250-,ul portions of the supernatant (S100) were stored at -20'C. Protein concentration in the S100 fraction was normally 1 to 3 mg/ml. Enzyme assays. Phosphocellulose paper binding assays were performed as described by Haas and Dowding (4) . All reaction mixtures consisted of 10 ,ul of phosphotransferase buffer, 10 ,ul of radiolabeled substrate, 10 ,ul of crude enzyme (Sl00), and 5 ,ul of antibiotic (1 mg/ml of free base). Assays were incubated at 350C for 30 min.
MATERUILS AND METHODS
Sephadex chromatography. A 4-ml amount of S100 was concentrated approximately 10-fold by dialysis against buffer I containing 20% polyethylene glycol (carbowax 6000), and the sample, containing 4.8 mg ofprotein, was applied to a 10-ml bed volume column of Sephadex G-100 swollen in buffer I. After ANTIMICROB. AGENTS CHEMOTHER. elution of the void volume (determined with blue dextran 2000) 2-min fractions (flow rate, 0.1 ml/min) were collected and assayed for enzyme activities.
Polyacrylamide gel electrophoresis. Lower gels (80 by 6 mm) were prepared by mixing 3 parts solution A (Tris, 12.1 g; 1 N HCI, 16 ml; tetramethyleneethylenediamine, 0.18 ml; water to 100 ml), 4 parts solution B (acrylamide, 15 g; methylenebisacrylamide, 0.4 g; water to 100 ml), and 1 part ammonium persulfate (0.56% in water). Stacking gels (12 by 6 mm) were prepared by mixing 2 parts solution C (Tris, 3 g; 1 N HCI, 24 ml; water to 100 ml), 3 parts solution D (acrylamide, 6.67 g, methylenebisacrylamide, 1 .67 g; water to 100 ml), 1 part riboflavin (4 mg/100 ml ofwater), and 2 parts water with the addition of 1 ,ul of dimethylaminopropionitrile (10% in water) per ml of gel. A total of 200 ,ll of S100 was layered onto the gel and electrophoresed at 2.5 mA/tube for 2 to 3 h at 4C. Buffer chambers contained 0.025 M Tris-0.019 M glycine, pH 8.3. After electrophoresis, gels were sliced to give 2-mm fractions; one-half of each fraction was assayed for aminoglycoside 6'-N-acetyltransferase and one-half was assayed for gentamicin phosphotransferase.
RESULTS
The three strains examined here all contain a similar aminoglycoside 6'-N-acetyltransferase (1). Table 1 shows the efficiencies of a number of aminoglycosides as substrates for this enzyme in vitro (for structures of aminoglycosides, see Fig. 3 and 4) . The fact that neomycin B is a substrate but that paromomycin is not suggests that acetylation occurs on the 6-amino group of the purpurosamine ring of gentamicin (ring I, Fig. 4) . Furthermore, when a number of purified components of the gentamicin complex were tested as substrates, it was found that increasing substitution at carbon 6 of this ring led to a decreasing ability of the compound to act as a substrate (gentamicin Cia, 100%; gentamicin C2, 16%; gentamicin Cl, 1%). In addition, 6'-N-acetylneomycin is known to retain considerable antibacterial activity, a fact that is compatible with the observation that strains C2 and C4, which both contain the acetyltransferase, are susceptible to neomycin.
In some gram-negative strains a single adenylyltransferase inactivates both streptomycin and spectinomycin (2) . In the strains examined here there are two enzymes of narrower substrate specificity. Strain Cl inactivates streptomycin by means of a specific adenylyltransferase that does not modify spectinomycin, and strain C2 inactivates spectinomycin by means of a distinct adenylyltransferase that does not modify streptomycin. Table 1 shows that strain Cl also contained an aminoglycoside 3'-phosphotransferase. The unusually high level of kanamycin phosphorylation by extracts of this strain prompted the testing of a number of other compounds of the kanamycin-gentamicin group for their ability to act as substrates. These assays revealed (Table 2) that in all three strains there was a phosphotransferase present capable of modifying the gentamicins, kanamycins, tobramycin, and BBK8 (amikacin). The two phosphotransferase activities from strain Cl were shown to be distinct by chromatography on Sephadex G-100 (see Fig. 1 ). Under these conditions, however, the gentamicin phosphotransferase and the acetyltransferase coeluted. This fact, coupled with the observation that all three strains contained both activities and the finding that they shared many common substrates, raised the possibility that only one enzyme was present, capable ofphosphorylating or acetylating a range of substrates, depending on the cofactor available. That two enzymes were, in fact, present was shown by separating the activities on a polyacrylamide gel (Fig. 2) .
The aminoglycosides may be divided into two structural groups (Fig. 3 and 4) , depending on the positions of the substitutions (4,5- Fig. 3 and 4) as is the case for the aminoglycoside 3'-phosphotransferases.
The four enzymes present in strain Cl appear to be produced constitutively. The addition of streptomycin, kanamycin, or neomycin (all at 10 ,ug/ml) to the growth medium resulted in no apparent overall increase in enzyme activity or change in the relative activities of any of the enzymes.
DISCUSSION
There has recently been a sudden increase in resistance to gentamicin among clinical isolates of S. aureus, and it is becoming apparent that this resistance is mediated by modifying enzymes similar to those found in many gramnegative strains. The strains studied here possess two mechanisms of resistance to gentamicin and related antibiotics. One of these is an enzyme that closely resembles aminoglycoside 6'-N-acetyltransferase (1) in that it appears to 6'-N-acetylate a similar range of compounds, including BBK8. The second mechanism is one that has not previously been detected in any strain, namely phosphorylation of the gentamicin-kanamycin group of antibiotics. The site at which this enzyme modifies is, as yet, unknown, but substrate studies suggest that it is either on deoxystreptamine or on the garosamine moiety of gentamicin. One possible site of modification is the 2'"-hydroxyl of garosamine (ring III, Fig. 4 ) as this group is known to be available for modification by gentamicin adenylyltransferase (8) .
The fact that both enzymes, with their very similar substrate ranges, are present in all three original isolates may be more than coincidence. Selection with gentamicin after transduction from strain Cl produced strain Ti, which also harbors both of the gentamicin-modifying enzymes but not the aminoglycoside 3'-phosphotransferase or the aminoglycoside 3"-ANTIMICROB. AGENTS CHEMOTHER. adenylyltransferase. The resistance phenotypes observed can, in theory, be explained by the possession of either of the enzymes alone, and it is possible that for some as yet unknown reason both are required for resistance. It is thus also possible that a re-examination of oher strains carrying aminoglycoside 6'-N-acetyltransferase may reveal that these, too, elaborate a gentamicin phosphotransferase.
